** Ebiogen Receives MFDS Manufacturing Approval for 6-Drug Rapid Screening Kit, BAROS-N6C-UriA
2026-10-27
본문
On October 20, 2026, Ebiogen received manufacturing approval from the Korean Ministry of Food and Drug Safety (MFDS) for BAROS-N6C-UriA, a medical device designed for the simultaneous rapid screening of six drugs.
BAROS-N6C-UriA is a urine-based rapid screening test capable of detecting MET, KET, MDMA, THC, MOR, and COC simultaneously, with results available in approximately 10 minutes.
The product has been designed for rapid on-site testing without the need for complex analytical equipment. Its simple testing procedure and easy-to-read format are intended to make the product accessible not only to professionals but also to general users.
BAROS-N6C-UriA is expected to have potential applications in a wide range of settings where rapid preliminary drug screening may be required, including military-related screening, pre-employment screening in public institutions and workplaces, and safety screening for personnel engaged in safety-sensitive or high-risk work environments.
As a rapid screening medical device, BAROS-N6C-UriA is intended for preliminary screening purposes, and additional confirmatory testing may be required depending on the test result and the applicable testing protocol.
With the approval of BAROS-N6C-UriA, Ebiogen plans to further expand the development and supply of rapid drug screening solutions that can be used easily and efficiently in field settings.
Ebiogen will continue to develop practical diagnostic and screening technologies that can contribute to the prevention of drug misuse and to the creation of safer communities.
